Element's Progress At JPM
Element discussed a few things at JPM:
Revenue and Shipments:
That revenue was $85M in 2025, up ~40%.
That the install base grew to 450 systems (up 60%).
Consumable shipments doubled.
That 35% of new shipments are multi-omics Aviti24s.
New products:
In Vitro Diagnostic Medical Device-certified version of the Aviti.
A new higher throughput benchtop instrument generating $100 genomes.
Multiomic analysis of FFPE and fresh frozen samples.
The revenue and shipment numbers seem quite solid. I assume Element has a solid few years of runway, but at $85M revenue it seems likely they are running at a loss of $100M+ a year.
From what I can tell, shipments numbers are not increasing1: